HSTM240920C30000
- 0.05
- 0.000.00%
HealthStream Newsroom
Barrington Maintains HealthStream(HSTM.US) With Hold Rating
HealthStream Financial Analysis: Hold Rating Maintained Amid Mixed Q2 Performance
Craig-Hallum Maintains HealthStream(HSTM.US) With Buy Rating, Announces Target Price $36
HealthStream Analyst Ratings
Canaccord Genuity Maintains Hold on HealthStream, Raises Price Target to $28
Maintaining Hold on HealthStream: Assessing Challenges and Growth Prospects
Barclays Maintains HealthStream(HSTM.US) With Buy Rating, Maintains Target Price $32
HealthStream (HSTM) Receives a Buy From Barclays
JMP Securities Maintains HealthStream(HSTM.US) With Hold Rating
JMP Securities Sticks to Their Hold Rating for HealthStream (HSTM)
Craig-Hallum Maintains HealthStream(HSTM.US) With Buy Rating
Barrington Sticks to Its Hold Rating for HealthStream (HSTM)
Analysts Conflicted on These Healthcare Names: HealthStream (HSTM) and Option Care Health (OPCH)
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Barclays Sticks to Its Buy Rating for HealthStream (HSTM)
JMP Securities Sticks to Its Hold Rating for HealthStream (HSTM)
Craig-Hallum Keeps Their Buy Rating on HealthStream (HSTM)
Balanced Outlook: Hold Rating on HealthStream Amidst Steady Performance and Growth Potential
Craig-Hallum Sticks to Its Buy Rating for HealthStream (HSTM)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA) and HealthStream (HSTM)